Patents by Inventor Charles John Guinosso
Charles John Guinosso has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 7101993Abstract: Compounds are provided containing purine nucleotides that bear moieties X at the 2? position thereof wherein X is R1—(R2)n; R1 is C3-C20 alkyl, C4-C20 alkenyl or C2-C20 alkynyl; R2 is halogen, hydroxyl, thiol, keto, carboxyl, nitro, nitroso, nitrile, trifluoromethyl, trifluoromethoxy, O-alkyl, S-alkyl, NH-alkyl, N-dialkyl, O-aryl, S-aryl, NH-aryl, O-aralkyl, S-aralkyl, NH-aralkyl, amino, N-phthalimido, imidazole, azido, hydrazino, hydroxylamino, isocyanato, sulfoxide, sulfone, sulfide, disulfide, silyl, aryl, heterocycle, carbocycle, intercalator, reporter molecule, conjugate, polyamine, polyamide, polyalkylene glycol, polyether, a group that enhances the pharmacodynamic properties of oligonucleotides, or a group that enhances the pharmacokinetic properties of oligonucleotides; and n is an integer from 0 to about 6. Such compounds are useful for modulating the synthesis of proteins.Type: GrantFiled: October 27, 1992Date of Patent: September 5, 2006Assignee: ISIS Pharmaceuticals, Inc.Inventors: Phillip Dan Cook, Daniel Peter Claude McGee, Charles John Guinosso
-
Publication number: 20040048826Abstract: Novel 2′-O-alkyl guanosine compounds are provided.Type: ApplicationFiled: September 15, 2003Publication date: March 11, 2004Applicant: ISIS Pharmaceuticals, Inc.Inventors: Phillip Dan Cook, Daniel Peter Claude McGee, Charles John Guinosso
-
Patent number: 6610663Abstract: Compositions and methods for modulating the activity of RNA are disclosed. In accordance with preferred embodiments, antisense compositions are prepared comprising targeting and reactive portions. The reactive portions preferably comprise one or two imidazole functionalities conjugated to the targeting oligonucleotide via linkers with or without intervening intercalating moieties. Therapeutics, diagnostics and research methods also are disclosed, as are synthetic nucleosides and nucleoside fragments that can be elaborated into oligonucleotides.Type: GrantFiled: October 10, 2001Date of Patent: August 26, 2003Assignee: ISIS Pharmaceuticals, Inc.Inventors: Phillip Dan Cook, Thomas Bruice, Charles John Guinosso, Andrew Mamoru Kawasaki, Richard Griffey
-
Publication number: 20020160972Abstract: Compositions and methods for modulating the activity of RNA are disclosed. In accordance with preferred embodiments, antisense compositions are prepared comprising targeting and reactive portions. The reactive portions preferably comprise one or two imidazole functionalities conjugated to the targeting oligonucleotide via linkers with or without intervening intercalating moieties. Therapeutics, diagnostics and research methods also are disclosed, as are synthetic nucleosides and nucleoside fragments that can be elaborated into oligonucleotides.Type: ApplicationFiled: October 10, 2001Publication date: October 31, 2002Applicant: ISIS Pharmaceuticals, Inc.Inventors: Phillip Dan Cook, Thomas Bruice, Charles John Guinosso, Andrew Mamoru Kawasaki, Richard Griffey
-
Patent number: 6358931Abstract: Compositions and methods for modulating the activity of RNA are disclosed, In accordance with preferred embodiments, antisense compositions are prepared targeting reactive portions. The reactive portions preferably comprise one or two imidazole functionalities conjugated to the targeting oligonucleotide via linkers with or without intervening intercalating moieties. Therapeutics, diagnostics and research methods also are disclosed, as are synthetic nucleosides and nucleoside fragments that can be elaborated into oligonucleotides.Type: GrantFiled: August 30, 1994Date of Patent: March 19, 2002Assignee: ISIS Pharmaceuticals, Inc.Inventors: Phillip Dan Cook, Thomas Bruice, Charles John Guinosso, Andrew Mamoru Kawasaki, Richard Griffey
-
Patent number: 6262241Abstract: Compositions and methods for modulating the activity of RNA and DNA are disclosed. In accordance with preferred embodiments, antisense compositions are prepared comprising targeting and reactive portions. Reactive portions which act, alternatively, through phosphorodiester bond cleavage, through backbone sugar bond cleavage or through base modification are preferrably employed. Groups which improve the pharmacodynamic and pharmacokinetic properties of the oligonucleotides are also useful in accordance with certain embodiments of this invention. Delivery of the reactive or non-reactive functionalities into the minor groove formed by the hybridization of the composition with the target RNA is also preferrably accomplished. Therapeutics, diagnostics and research methods and also disclosed. Synthetic nucleosides and nucleoside fragments are also provided useful for elaboration of oligonucleotides and oligonucleotide analogs for such purposes.Type: GrantFiled: February 3, 1995Date of Patent: July 17, 2001Assignee: Isis Pharmaceuticals, Inc.Inventors: Phillip Dan Cook, David J. Ecker, Charles John Guinosso, Oscar Leobardo Acevedo, Andrew Kawasaki, Kandasamy Ramasamy
-
Patent number: 6242592Abstract: Processes for preparing 2′-O-alkylated guanosine, uridine, cytidine, and 2,6-diaminopurine 3′-O-phosphoramidites include the steps of alkylating nucleoside precursors, adding suitable blocking groups and phosphitylating. For the guanosine 2′-O-alkylated 3′-O-phosphoramidites, alkylation is effected on 2,6-diamino-9-(&bgr;-D-ribofuranosyl) purine followed by deamination. For uridine 2′-O-alkylated 3′-O-phosphoramidites, alkylation is effect on a dialkyl stannylene derivative of uridine. For cytidine 2′-O-alkylated 3′-O-phosphoramidites, alkylation is effected directly on cytidine. Alkylation is effected directly upon 2,6-diaminopurine.Type: GrantFiled: December 9, 1999Date of Patent: June 5, 2001Assignee: ISIS Pharmaceuticals, Inc.Inventors: Phillip Dan Cook, Daniel Peter Claude McGee, Charles John Guinosso
-
Patent number: 6156758Abstract: Provided are compounds of formula (I) ##STR1## wherein X, Y and Z are independently CH or N; n is 0 or 1; R.sub.1 is selected from OH, alkoxy, aryloxy, aralkyloxy and guanidinyl; R.sub.2 and R.sub.3 are independently selected from H, halogen, amino, hydroxyl, nitro, cyano and carboxyl; R.sub.4 is H, alkyl or acyl; R.sub.5 is selected from H, hydroxyl, halogen, nitro, alkyl, alkoxy, amino, cyclic amino, alkylamino, arylamino and aralkylamino wherein the alkyl, aryl and cyclic moieties are optionally substituted; R.sub.6 and R.sub.7 are independently selected from H, alkyl, alkoxy, halogen and amino; and R.sub.8 and R.sub.9 are independently selected from H, C.sub.1-4 alkyl, alkoxy, acyl, acyloxy, alkoxycarbonyl, hydroxyl, halogen, amino and carboxyl. The compounds have therapeutic or prophylactic use for treating bacterial infection in mammals.Type: GrantFiled: September 8, 1999Date of Patent: December 5, 2000Assignee: Isis Pharmaceuticals, Inc.Inventors: Pei-Pei Kung, Phillip Dan Cook, Charles John Guinosso
-
Patent number: 6133438Abstract: Processes for preparing 2'-O-alkylated guanosine, uridine, cytidine, and 2,6-diaminopurine 3'-O-phosphoramidites include the steps of alkylating nucleoside precursors, adding suitable blocking groups and phosphitylating. For the guanosine 2'-O-alkylated 3'-O-phosphoramidites, alkylation is effected on 2,6-diamino-9-(.beta.-D-ribofuranosyl)purine followed by deamination. For uridine 2'-O-alkylated 3'-O-phosphoramidites, alkylation is effect on a dialkyl stannylene derivative of uridine. For cytidine 2'-O-alkylated 3'-O-phosphoramidites, alkylation is effected directly on cytidine. Alkylation is effected directly upon 2,6-diaminopurine.Type: GrantFiled: October 2, 1998Date of Patent: October 17, 2000Assignee: Isis Pharmaceuticals, Inc.Inventors: Phillip Dan Cook, Daniel Peter Claude McGee, Charles John Guinosso
-
Patent number: 5914396Abstract: 2'-O-Modified nucleosides, nucleotides, and oligonucleotides. These 2'-O-modified oligonucleotides are resistant to nuclease digestion and can effectively hybridize to a complementary polynucleotide.Type: GrantFiled: February 22, 1995Date of Patent: June 22, 1999Assignee: ISIS Pharmaceuticals, Inc.Inventors: Phillip Dan Cook, Charles John Guinosso
-
Patent number: 5856466Abstract: Processes for preparing 2'-O-alkylated guanosine, uridine, cytidine, and 2,6-diaminopurine 3'-O-phosphoramidites include the steps of alkylating nucleoside precursors, adding suitable blocking groups and phosphitylating. For the guanosine 2'-O-alkylated 3'-O-phosphoramidites, alkylation is effected on 2,6-diamino-9-(.beta.-D-ribofuranosyl)purine followed by deamination. For uridine 2'-O-alkylated 3'-O-phosphoramidites, alkylation is effect on a dialkyl stannylene derivative of uridine. For cytidine 2'-O-alkylated 3'-O-phosphoramidites, alkylation is effected directly on cytidine. Alkylation is effected directly upon 2,6-diaminopurine.Type: GrantFiled: July 7, 1997Date of Patent: January 5, 1999Assignee: Isis Pharmaceuticals, Inc.Inventors: Phillip Dan Cook, Daniel Peter Claude McGee, Charles John Guinosso